PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Ann Oncol 2016; 27: 1519–1525 (doi: 10.1093/annonc/mdw197)

In the original article, the following funding information was omitted: This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. This has now been added.